Alps Advisors Inc. Invests $164,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Alps Advisors Inc. acquired a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTXGet Rating) in the second quarter, HoldingsChannel.com reports. The firm acquired 31,260 shares of the company’s stock, valued at approximately $164,000.

A number of other large investors also recently modified their holdings of MLTX. TD Asset Management Inc. acquired a new position in shares of MoonLake Immunotherapeutics during the 2nd quarter worth about $152,000. Meridian Wealth Management LLC acquired a new position in shares of MoonLake Immunotherapeutics during the 2nd quarter worth about $142,000. Finally, Cowen AND Company LLC acquired a new position in shares of MoonLake Immunotherapeutics during the 2nd quarter worth about $85,000.

MoonLake Immunotherapeutics Stock Up 1.6 %

Shares of MLTX stock opened at $8.43 on Thursday. The firm’s 50-day moving average is $8.16 and its 200-day moving average is $6.99. MoonLake Immunotherapeutics has a 52-week low of $4.25 and a 52-week high of $15.19.

Analyst Upgrades and Downgrades

MLTX has been the subject of a number of recent research reports. SVB Leerink began coverage on shares of MoonLake Immunotherapeutics in a research note on Thursday, August 25th. They set an “outperform” rating and a $17.00 price objective for the company. Jefferies Financial Group began coverage on shares of MoonLake Immunotherapeutics in a report on Friday, November 11th. They issued a “buy” rating and a $16.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Buy” and a consensus target price of $20.33.

MoonLake Immunotherapeutics Profile

(Get Rating)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.

Featured Articles

Want to see what other hedge funds are holding MLTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MoonLake Immunotherapeutics (NASDAQ:MLTXGet Rating).

Institutional Ownership by Quarter for MoonLake Immunotherapeutics (NASDAQ:MLTX)

Receive News & Ratings for MoonLake Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MoonLake Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.